Literature DB >> 8632903

The human tumour suppressor gene p53 is alternatively spliced in normal cells.

J M Flaman1, F Waridel, A Estreicher, A Vannier, J M Limacher, D Gilbert, R Iggo, T Frebourg.   

Abstract

Alternative splicing affecting the p53 carboxy-terminus has previously been described in mouse but not in normal human cells. We report here the detection in normal human lymphocytes of an alternatively spliced form of human p53 mRNA containing an additional 133 bp exon derived from intron 9. This splice variant encodes a truncated protein of 341 amino-acids including 10 new amino-acids derived from the novel exon. The truncated protein, which lacks part of the p53 tetramerization domain, fails to bind DNA in vitro and has a transcriptional defect in vivo in both yeast and mammalian cells. Quantitative RT-PCR experiments suggest that the alternatively spliced form is only present in significant amounts in quiescent cells. Considering the numerous functions ascribed to the carboxy-terminus of the p53 protein, this splice variant may have important implications for the biological role of p53 in normal cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632903

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast.

Authors:  Jana Smardová; Sárka Pavlová; Hana Koukalová
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

2.  p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes.

Authors:  Pierre-Jacques Hamard; Dana J Lukin; James J Manfredi
Journal:  J Biol Chem       Date:  2012-04-18       Impact factor: 5.157

3.  The history of p53. A perfect example of the drawbacks of scientific paradigms.

Authors:  Thierry Soussi
Journal:  EMBO Rep       Date:  2010-10-08       Impact factor: 8.807

Review 4.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

5.  The C terminus of p53 family proteins is a cell fate determinant.

Authors:  Kelly Lynn Harms; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

6.  The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells.

Authors:  N Almog; R Li; A Peled; D Schwartz; R Wolkowicz; N Goldfinger; H Pei; V Rotter
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

Review 7.  Senescence regulation by the p53 protein family.

Authors:  Yingjuan Qian; Xinbin Chen
Journal:  Methods Mol Biol       Date:  2013

8.  TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors:  Hervé Bonnefoi; Martine Piccart; Jan Bogaerts; Louis Mauriac; Pierre Fumoleau; Etienne Brain; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Khalil Zaman; Tanja Cufer; Alain Lortholary; Elisabet Lidbrink; Sylvie André; Saskia Litière; Lissandra Dal Lago; Véronique Becette; David A Cameron; Jonas Bergh; Richard Iggo
Journal:  Lancet Oncol       Date:  2011-05-11       Impact factor: 41.316

9.  p53 isoforms can regulate p53 transcriptional activity.

Authors:  Jean-Christophe Bourdon; Kenneth Fernandes; Fiona Murray-Zmijewski; Geng Liu; Alexandra Diot; Dimitris P Xirodimas; Mark K Saville; David P Lane
Journal:  Genes Dev       Date:  2005-08-30       Impact factor: 11.361

Review 10.  p53 Family isoforms.

Authors:  Jean-Christophe Bourdon
Journal:  Curr Pharm Biotechnol       Date:  2007-12       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.